Top Clinical Trials companies in Switzerland by Revenue

This ranking features the top 18 Clinical Trials companies in Switzerland ranked by Revenue, totaling a Revenue of USD 123.93 B, for July 08, 2025.

#	Name	Market Capitalization Share Price Year-To-Date (YTD) return Price to Earnings Ratio (P/E) Revenue Year-on-Year (YoY) growth Operating Income EBIT EBITDA Free Cash Flow Dividend Yield Free Cash Flow Yield Total Assets Total Liabilities Cash and Short-Term Investments	Stock Price	Change	Price (30 days)	52W low/high	Sector

Items per page

Frequently Asked Questions

Which Clinical Trials company in Switzerland has the highest Revenue ?

The Clinical Trials company in Switzerland with the highest Revenue is Roche Holding AG (Swiss Stock Exchange: RO.SW) at USD 68.70 B.

Which Clinical Trials company in Switzerland has the lowest Revenue ?

The Clinical Trials company in Switzerland with the lowest Revenue is MoonLake Immunotherapeutics (NasdaqCM: MLTX) at None.

What are the top 10 Clinical Trials companies in Switzerland by Revenue ?

The top 10 Clinical Trials companies in Switzerland by Revenue are Roche Holding AG, Novartis AG, Siegfried Holding AG, Bachem Holding AG, Medacta Group SA, Basilea Pharmaceutica AG, IVF Hartmann Holding AG, Idorsia Ltd, Kuros Biosciences AG and ADC Therapeutics SA.

What are the bottom 10 Clinical Trials companies in Switzerland by Revenue ?

The bottom 10 Clinical Trials companies in Switzerland by Revenue are MoonLake Immunotherapeutics, NLS Pharmaceutics AG, Oculis Holding AG, Addex Therapeutics Ltd, Molecular Partners AG, AC Immune SA, CRISPR Therapeutics AG, Santhera Pharmaceuticals Holding AG, ADC Therapeutics SA and Kuros Biosciences AG.